SC 13G/A: Alaunos Therapeutics, Inc.

AI Summary

SC 13G/A filing by Alaunos Therapeutics, Inc..

Risk Assessment

Risk Level: low

FAQ

Key Financial Figures

• $0.001 — Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class o

Filing Documents

• d834368dsc13ga.htm (SC 13G/A) — 82KB
• d834368dex991.htm (EX-99.1) — 6KB
• 0001193125-24-258550.txt ( ) — 90KB

From the Filing

SC 13G/A 1 d834368dsc13ga.htm SC 13G/A SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Alaunos Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 98973P309 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No: 98973P309 1 NAMES OF REPORTING PERSONS MSD Partners, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)(b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER - 0 - 6 SHARED VOTING POWER 101,010 7 SOLE DISPOSITIVE POWER - 0 - 8 SHARED DISPOSITIVE POWER 101,010 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 101,010 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.3% (1) 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN (1) The percentages used herein are calculated based upon 1,601,252 shares of the issuers common stock outstanding as of August 13, 2024, as reported in the issuers Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2024. CUSIP No: 98973P309 1 NAMES OF REPORTING PERSONS MSD Credit Opportunity Master Fund, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)(b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER - 0 - 6 SHARED VOTING POWER 101,010 7 SOLE DISPOSITIVE POWER - 0 - 8 SHARED DISPOSITIVE POWER 101,010 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 101,010 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.3% (1) 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN (1) The percentages used herein are calculated based upon 1,601,252 shares of the issuers common stock outstanding as of August 13, 2024, as reported in the issuers Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2024. CUSIP No: 98973P309 1 NAMES OF REPORTING PERSONS Gregg R. Lemkau 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)(b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION United NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER - 0 - 6 SHARED VOTING POWER 101,010 7 SOLE DISPOSITIVE POWER - 0 - 8 SHARED DISPOSITIVE POWER 101,010 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 101,010 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.3% (1) 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN (1) The percentages used herein are calculated based upon 1,601,252 shares of the issuers common stock outstanding as of August 13, 2024, as reported in the issuers Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2024. Item1(a) Name of Issuer: The name of the issuer is Alaunos Therapeutics, Inc. (the Company). Item1(b) Address of Issuers Principal Executive Offices: The Companys principal executive office is located at 2617 Bissonnet Street, Suite 225 Houston, TX 77005. Item2(a) Name of Person Filing: This Schedule 13G is being jointly filed by and on behalf of each of MSD Partners, L.P. (MSD Partners), MSD Credit Opportunity Master Fund, L.P. (MSD Credit Opportunity Master Fund) and Gregg R. Lemkau. MSD Credit Opportunity Master Fund is the direct owner of the securities covered by this statement. MSD Partners is the investment manager of, and may be deemed to beneficially own securities beneficially owned by, MSD Credit Opportunity Master Fund. MSD Partners (GP), LLC (MSD GP) is the general partner of, and

View Full Filing

View this SC 13G/A filing on SEC EDGAR